Abstract
In clinical practice and for scientific purposes, cardiologists and primary care physicians perform risk assessment in patients with cardiac diseases or conditions with high risk of developing such. The European Heart Rhythm Association (EHRA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS) set down this expert consensus statement task force to summarize the consensus regarding risk assessment in cardiac arrhythmias. Objectives were to raise awareness of using the right risk assessment tool for a given outcome in a given population, and to provide physicians with practical proposals that may lead to rational and evidence-based risk assessment and improvement of patient care in this regard. A large variety of methods are used for risk assessment and choosing the best methods and tools hereof in a given situation is not simple. Even though parameters and test results found associated with increased risk of one outcome (e.g. death) may also be associated with higher risk of other adverse outcomes, specific risk assessment strategies should be used only for the purposes for which they are validated. The work of this task force is summarized in a row of consensus statement tables.
Highlights
Several studies have shown that PR prolongation in patients undergoing cardiac pacing or receiving cardiac resynchronization therapy (CRT) is an independent predictor of worse prognosis and lower probability of reverse remodelling as well as an increased risk of atrial fibrillation (AF), death, and hospitalization.[30,31]
electrophysiological study (EPS) is not recommended for additional risk stratification in patients with either long or short QT, catecholaminergic ventricular tachyarrhythmias (VTs) or early repolarization
EPS is not recommended for risk stratification in patients with ischaemic or non-ischaemic dilated cardiomyopathy 40 (DCM) who meet criteria for implantable cardioverter-defibrillator (ICD) implantation
Summary
5.5 Patients with inherited arrhythmia diseases (Inherited channelopathies and inherited structural diseases including arrhythmogenic right ventricular cardiomyopathy). 5.6 Risk stratification in patients with arrhythmogenic cardiomyopathy, specified for arrhythmogenic right ventricular cardiomyopathy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
